SciClone's Quarter Sales Growth Marred By FCPA Investigation Of China Operations

HONG KONG - U.S. regulatory authorities have launched an investigation into the China operations of Hong Kong-based and Nasdaq-listed SciClone Pharmaceuticals, a specialty pharmaceutical company